Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Hadassah Medical Organization Identifier:
First received: August 5, 2012
Last updated: August 7, 2012
Last verified: August 2012
The goal of the investigators research is to explore energy production of the ovarian follicle in older reproductive age women at the time of oocyte retrieval.

Condition Intervention
Ovarian Function at Advanced Reproductive Age
Dietary Supplement: Coenzyme Q10 concomitant treatment
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • level of ATP production [ Time Frame: 2 years ]
  • Steriodogenesis associated enzymatic activity [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Ovarian Response [ Time Frame: 2 years ]
  • Embryo quality [ Time Frame: 2 years ]
  • cumulative pregnancy rate per retrieval [ Time Frame: 2 years ]
  • cumulative live birth rate per retrieval [ Time Frame: 2 years ]

Other Outcome Measures:
  • Co Enzyme Q10 levels in maternal serum by HPLC [ Time Frame: 2 years ]

Estimated Enrollment: 100
Study Start Date: September 2012
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Coenzyme Q10 concomitant treatment

Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment

Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.

Other name: Ubiquinone

Dietary Supplement: Coenzyme Q10 concomitant treatment
Placebo Comparator: Placebo
1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
Dietary Supplement: Placebo


Ages Eligible for Study:   38 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 38-43 years at the time of enrollment
  • Diagnosis of primary infertility

Exclusion Criteria:

  • Body mass index (BMI) > 30 kg/m2
  • Early follicular phase (day 2-4) serum FSH level > 20 mIU/ml.
  • Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
  • Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment.
  • Any contraindication to being pregnant and carrying a pregnancy to term.
  • Contraindication for the use of CoQ10, or fertility medications.
  • Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.
  • Absence of one or two ovaries
  • Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, polycystic ovarian syndrome, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).
  • History (within past 12 months) or current abuse of alcohol or drugs.
  • Administration of any investigational drugs within three months prior to study enrollment.
  • Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction
  • Unexplained gynecological bleeding.
  • Ejaculated sperm is not sufficient for ICSI
  • Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
  • Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study.
  • Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
  • The concurrent use of any of the following drugs:
  • Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine) multivitamins or any vitamin supplementation except Folic acid.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01659788

Contact: Ronit Kochman, MD 00 972 50 8946414

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel
Contact: Hadas Lamberg, PhD    00 972 2 677572   
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Ronit Kochman, MD Hadassah Medical Organization
  More Information

Responsible Party: Hadassah Medical Organization Identifier: NCT01659788     History of Changes
Other Study ID Numbers: CoEnzyme Q10-HMO-CTIL
Study First Received: August 5, 2012
Last Updated: August 7, 2012

Keywords provided by Hadassah Medical Organization:
Advanced Reproductive Age
poor ovarian response
Mitochondrial dysfunction
Mitochondrial nutrients
Coenzyme Q10
Electron transfer chain

Additional relevant MeSH terms:
Coenzyme Q10
Growth Substances
Physiological Effects of Drugs
Vitamins processed this record on April 27, 2017